Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
August 22, 2022Release of an ad hoc announcement pursuant to Art. 53 LRRELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (OTCQB: RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx"), today announced that they have agreed to a tentative...
-
August 15, 2022Company to Host Conference Call and Webcast August 15, 2022, at 8:30am ET
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the second quarter of 2022...
-
August 10, 2022
In the news release, NRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022, issued Aug. 10, 2022 by NRx Pharmaceuticals, Inc. over PR Newswire, we are advised by the company...
-
July 13, 2022Extensive experience in Law, Finance, and Management of Public and Private Biotechnology Companies Proven track record of creating value for shareholders National Science Board Presidential...
-
July 1, 2022Focus is now on NRX-101 for Bipolar Depression with Suicidality
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has declined to issue...
Click here to view our corporate presentation or on the image below
 |
